顺式-3-氨基环戊烷甲酸甲酯盐酸盐 | 222530-29-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 顺式-3-氨基环戊烷甲酸甲酯盐酸盐
• 中文别名: (1R,3S)-3-氨基环戊烷-1-羧酸甲酯盐酸盐
• 英文名称: (1R,3S)-methyl 3-aminocyclopentanecarboxylate hydrochloride
• 英文别名: methyl (1R,3S)-3-aminocyclopentanecarboxylate hydrochloride；methyl (1R,3S)-3-aminocyclopentane-1-carboxylate;hydrochloride
• CAS: 222530-29-2；180196-56-9
• 化学式: C₇H₁₃NO₂*ClH
• 分子量: 179.647
• InChiKey: CKMCJNXERREXFB-IBTYICNHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.71
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  52.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  顺式-3-氨基环戊烷甲酸甲酯盐酸盐 在 一水合肼 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 N-((1S,3R)-3-(hydrazinecarbonyl)cyclopentyl)acetamide
  参考文献：
  名称：

  [EN] INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE
  [FR] THIADIAZOLAMINES INDAZOLYLE ET COMPOSÉS APPARENTÉS POUR L'INHIBITION DE PROTÉINE KINASE ASSOCIÉE À RHO ET LE TRAITEMENT DE MALADIES

  摘要：

  这项发明提供了吲唑基噻二唑胺及相关化合物、药物组合物、抑制Rho相关蛋白激酶的方法，以及利用这些化合物治疗炎症性疾病、免疫性疾病、纤维化疾病和其他医学疾病的方法。一种示例性的吲唑基噻二唑胺化合物是N-(5-[5-[(1H-吲唑-5-基)氨基]-1,3,4-噻二唑-2-基]吡啶-3-基)乙酰胺化合物。

  公开号：

  WO2016138335A1
• 作为产物：
  描述：

  (1S,4R)-N-(9-Phenylfluoren-9-yl)-2-azabicyclo<2.2.1>heptan-3-one 在 盐酸 、 溶剂黄146 作用下， 以 various solvent(s) 为溶剂， 反应 36.0h， 生成 顺式-3-氨基环戊烷甲酸甲酯盐酸盐
  参考文献：
  名称：

  Chirospecific synthesis of (1S,3R)-1-amino-3-(hydroxymethyl)cyclopentane, precursor for carbocyclic nucleoside synthesis. Dieckmann cyclization with an .alpha.-amino acid

  摘要：

  Carbocyclic nucleosides are important isosteres of nucleosides possessing a variety of antiviral and antineoplastic activities. We report here a new method for the chirospecific synthesis of (1S,3R)-1-amino-3-(hydroxymethyl)cyclopentane. This compound is a key precursor for the synthesis of some carbocyclic nucleosides. The method involves (1) an improved synthesis of (S)-2-aminoadipic acid; (2) Dieckmann cyclization of this alpha-amino acid to an aminocyclopentanone; and (3) elaboration of the latter to the target (1S,3R)-l-amino-3-(hydroxymethyl)cyclopentane. The starting (S)-2-aminoadipic acid delta-methyl ester was prepared enantiomerically pure from (S)-aspartic acid in 51% overall yield. Dieckmann condensation converted this amino acid to a (methoxycarbonyl)-cyclopentanone, and reduction of the ketone followed by elimination yielded (S)-3-[N-(9-phenylfluoren-9-yl)amino]-1-(methoxycarbonyl)cyclopentene. Reduction of the double bond gave a mixture of the cis and trans diastereomers. This mixture was converted to a single diastereomer by epimerization and trapping of the cis isomer as (1S,4R)-2-(9-phenylfluoren-9-yl)-2-azabicyclo[2.2.1]heptan-3-one. Hydrolytic cleavage of the lactam followed by reduction gave (IS,3R)-1-amino-3-(hydroxymethyl)-cyclopentane.

  DOI：

  10.1021/jo00061a006

文献信息

• Prescreening of Nicotine Hapten Linkers in Vitro To Select Hapten-Conjugate Vaccine Candidates for Pharmacokinetic Evaluation in Vivo
  作者：Viswanath Arutla、Joseph Leal、Xiaowei Liu、Sriram Sokalingam、Michael Raleigh、Adejimi Adaralegbe、Li Liu、Paul R. Pentel、Sidney M. Hecht、Yung Chang

  DOI：10.1021/acscombsci.6b00179

  日期：2017.5.8

  (ELISA) to profile the interactions of nicotine haptens or hapten-protein conjugates with nicotine specific antibodies, both polyclonal and monoclonal. Another relies on computational modeling of the interactions between haptens and amino acid residues near the conjugation site of the carrier protein to infer linker-carrier protein conjugation effect on antinicotine antibody response. Using these two in

  自从证明尼古丁疫苗可作为治疗烟草烟雾影响的干预措施以来，人们为提高尼古丁特异性免疫力做出了巨大努力。尼古丁半抗原的接头修饰已成为改善尼古丁免疫原性的焦点，其中这些修饰的评估通常依赖于体内动物模型，例如小鼠，大鼠或非人灵长类动物。在这里，我们提出两种体外筛选策略，以评估和预测我们新设计的尼古丁半抗原的免疫原性。一种利用竞争性酶联免疫吸附测定法（ELISA）来分析尼古丁半抗原或半抗原-蛋白质缀合物与尼古丁特异性抗体（多克隆和单克隆）的相互作用。另一个依赖于半抗原与载体蛋白结合位点附近的氨基酸残基之间相互作用的计算模型，以推断接头-载体蛋白对抗烟碱抗体应答的结合作用。使用这两种体外方法，我们对具有不同连接子的半抗原作为有潜力的候选疫苗进行了排名。基于ELISA的半抗原排名与通过体内尼古丁药代动力学分析获得的结果一致。发现平均结合亲和力（IC 基于ELISA的半抗原排名与通过体内尼古丁药代动力学分
• [EN] NOVEL OXADIAZOLE COMPOUNDS<br/>[FR] COMPOSÉS INÉDITS D'OXADIAZOLE
  申请人：ABBOTT LAB

  公开号：WO2011071570A1

  公开（公告）日：2011-06-16

  Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.

  新型噁二唑化合物，含有这种化合物的药物组合物以及将这些化合物或组合物用作治疗与调节S1P家族G蛋白偶联受体活性相关的疾病的激动剂或拮抗剂的用途被披露，特别是通过提供有益的免疫抑制作用。
• Tetrahydroquinazolinone Derivatives as PARP Inhibitors
  申请人：Lupin Limited

  公开号：US20150152118A1

  公开（公告）日：2015-06-04

  Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R 1 -R 6 , R 7a-d , R 8a-d , A, M, n, and p are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.

  公开了式（I）的化合物，其互变异构体、立体异构体和其药学上可接受的盐，其中R1-R6、R7a-d、R8a-d、A、M、n和p如规范中所定义，包括一种化合物、互变异构体、立体异构体或其盐的药物组合物，以及治疗或预防疾病或紊乱的方法，例如癌症，这些疾病或紊乱可通过抑制受试者的PARP酶来治疗或预防。
• [EN] TETRAHYDROQUINAZOLINONE DERIVATIVES AS PARP INHIBITORS<br/>[FR] DÉRIVÉS TÉTRAHYDROQUINAZOLINONE UTILISÉS COMME INHIBITEURS DE PARP
  申请人：LUPIN LTD

  公开号：WO2014009872A1

  公开（公告）日：2014-01-16

  Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R6, R7a-d, R8a-d, A, M, n, and p are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.

  公开的是式(I)的化合物，它们的互变异构体、立体异构体和药学上可接受的盐，其中R1-R6、R7a-d、R8a-d、A、M、n和p如规范中所定义，包括一种化合物、互变异构体、立体异构体或其盐的药物组合物，以及治疗或预防疾病或疾病的方法，例如癌症，通过抑制受试者的PARP酶可治疗或预防的疾病。
• [EN] ARYL-PHENYL-SULFONAMIDO-CYCLOALKYL COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS ARYL-PHÉNYL-SULFONAMINO-CYCLOALKYLE ET LEURS UTILISATIONS
  申请人：PIMCO 2664 LTD

  公开号：WO2010032009A1

  公开（公告）日：2010-03-25

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as "APSAC compounds"). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc. Formula (I).

  本发明一般涉及治疗化合物领域，更具体地涉及以下化学式的某些芳基-苯基-磺酰胺基-环烷基化合物（以下统称为“APSAC化合物”）。本发明还涉及包含这种化合物的药物组合物，以及这种化合物和组合物的使用，无论是在体外还是体内，用于治疗炎症和/或关节破坏和/或骨质流失等疾病，过度和/或不适当和/或持续激活免疫系统介导的疾病，例如炎症性和自身免疫性疾病，如类风湿关节炎、银屑病、银屑病性关节炎、慢性阻塞性肺病（COPD）、动脉粥样硬化、炎症性肠病、强直性脊柱炎等；与骨质流失相关的疾病，例如类风湿性关节炎中由过度破骨细胞活动引起的骨质流失、骨质疏松症、癌症相关的骨病、帕金森病等等；以及癌症，如血液恶性肿瘤、实体肿瘤等。化学式（I）。